Hypothesis

We propose that a nucleolar-localized long non‑coding RNA, termed AGE‑REG1, functions as a single upstream controller that coordinates the NLRP3 inflammasome, IL‑6‑STAT3 signaling, and epigenetic drift. Rather than treating each hallmark as an independent process, AGE‑REG1 integrates mitochondrial ROS sensing, inflammasome assembly, cytokine transcription, and chromatin remodeling to drive a coordinated aging program.

Mechanistic Model

• ROS sensing: Mitochondrial ROS oxidize specific residues on AGE‑REG1, promoting its release from nucleoli to the cytoplasm.
• Inflammasome scaffolding: Cytoplasmic AGE‑REG1 binds NLRP3 and ASC via RNA‑protein interaction domains, lowering the threshold for oligomerization and caspase‑1 activation {1}.
• IL‑6 amplification: AGE‑REG1 also interacts with the IL‑6 promoter enhancer, recruiting NF‑κB and STAT3 complexes, thereby enhancing transcription {4}.
• Epigenetic coupling: In the nucleus, AGE‑REG1 guides DNMT3A/TET2 to CpG islands of aging‑related genes, altering DNA methylation patterns that correlate with epigenetic clocks {6}.
• Feedback loops: IL‑6‑STAT3 signaling further increases AGE‑REG1 transcription, creating a self‑reinforcing circuit that explains the observed correlations between inflammasome activity, cytokine load, and epigenetic age.

This model extends the current view of NLRP3 and IL‑6 as interconnected hubs by positioning AGE‑REG1 as the molecular linchpin that translates mitochondrial stress into inflammasome activation, cytokine production, and epigenetic reprogramming.

Testable Predictions

1. Expression: AGE‑REG1 levels rise with chronological age in multiple tissues (e.g., spleen, liver, brain) and correlate with NLRP3 activation, IL‑6 serum levels, and DNA methylation age.
2. Loss‑of‑function: Knockdown or CRISPR‑mediated deletion of AGE‑REG1 in aged mice reduces NLRP3 oligomerization, caspase‑1 activity, and IL‑6 secretion, while slowing epigenetic clock advancement.
3. Gain‑of‑function: Forced expression of AGE‑REG1 in young animals precipitates NLRP3‑dependent inflammation, elevates IL‑6, accelerates epigenetic aging, and shortens healthspan.
4. Rescue: Re‑introduction of wild‑type AGE‑REG1, but not a mutant deficient in NLRP3 binding, restores the aged phenotype in knockout backgrounds.
5. Organ specificity: Temporal patterns of AGE‑REG1 upregulation match organ‑specific hallmark trajectories reported in single‑cell aging atlases {7}.

Experimental Design

• Correlative analysis: Quantify AGE‑REG1 by RT‑qPCR and RNA‑seq across young (3 mo) and old (24 mo) C57BL/6 mice in spleen, liver, hippocampus, and blood; correlate with NLRP3 ASC speck formation (imaging), caspase‑1 activity (FLICA assay), serum IL‑6 (ELISA), and Horvath‑style DNA methylation arrays.
• Loss‑of‑function: Generate AGE‑REG1 floxed mice crossed with tamoxifen‑inducible Cre‑ER lines; assess inflammasome activity, IL‑6, frailty index, and lifespan after induction at 18 mo.
• Gain‑of‑function: Use AAV9‑mediated liver‑specific overexpression of AGE‑REG1 in 6‑mo mice; monitor downstream phenotypes over 6 months.
• Mechanistic assays: Perform RNA immunoprecipitation (RIP) to confirm AGE‑REG1 binding to NLRP3, ASC, IL‑6 promoter, and DNMT3A/TET2; use mutagenesis to map domains required for each interaction.
• Pharmacological test: Treat aged wild‑type mice with a locked nucleic acid (LNA) gapmer targeting AGE‑REG1; compare outcomes to MCC950 treatment to determine whether AGE‑REG1 inhibition phenocopies NLRP3 blockade.

Falsifiability

If AGE‑REG1 expression does not increase with age, or its manipulation fails to alter NLRP3 activation, IL‑6 levels, or epigenetic age in the predicted directions, the hypothesis would be refuted. Conversely, consistent support across these assays would position AGE‑REG1 as a plausible upstream controller unifying multiple hallmarks of aging.